Full Press Release Details
Blue Water Vaccines Announces Plans to Evaluate
Efficacy of Streptococcus pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia at the World Vaccine Congress in Barcelona
CINCINNATI, OH, October 11, 2022
-- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical
company developing transformational vaccines to address significant global health challenges, today announced plans to investigate
the ability of BWV-201, a Streptococcus pneumoniae vaccine candidate for acute otitis media ("AOM") prevention, to
also protect against non-invasive pneumococcal pneumonia at the World Vaccine Congress in Barcelona.
While Streptococcus pneumoniae is commonly found in the nose
and throat of healthy individuals, overgrowth and spread of the bacteria can result in pneumococcal disease. Non-invasive forms of pneumococcal
disease include AOM, sinusitis, and pneumococcal pneumonia, while invasive forms include bacteremia, sepsis, and pneumococcal meningitis.
BWV's new development plan aims to assess the efficacy of BWV-201 in protecting individuals against non-invasive pneumococcal pneumonia.
BWV-201 is a live attenuated bacterial vaccine candidate developed
for the prevention of AOM in children caused by Streptococcus pneumoniae. New data, based on experiments at St. Jude Children's
Research Hospital, suggests that BWV-201 may also provide protection against pneumococcal pneumonia by limiting the ability of Streptococcus
pneumoniae to infect the lungs.
While conjugate and polysaccharide vaccines are available to protect
against pneumococcal disease, protection is mainly limited to invasive disease. Efficacy rates of these vaccines against pneumococcal
pneumonia are historically only between 0% and 50%, as these vaccines are administered intramuscularly and elicit a strong systemic response,
but poor protection at the mucosal surface where pneumonia infection begins. Additionally, these vaccines only provide protection against
serotypes included in the vaccine, ranging from 13 to 23 serotypes. By administering the modified live bacteria intranasally, BWV-201
is designed to elicit a strong mucosal immune response, regardless of capsular polysaccharide serotype.
"While current pneumococcal vaccines have demonstrated excellent
efficacy against invasive pneumococcal disease historically, pneumococcal pneumonia remains a significant unmet medical need," said
Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines. "With this new data, we believe our vaccine can provide
protection across all Streptococcus pneumoniae strains and eliminate the need for antibiotic treatment associated with pneumococcal
pneumonia. We are excited to further develop BWV-201 for this new indication and look forward to addressing this need."
According to the Centers for Disease Control and Prevention, non-invasive
pneumococcal pneumonia causes an estimated 150,000 hospitalizations each year in the United States alone. Despite vaccination efforts
with traditional pneumococcal vaccines, the American Lung Association reports that adults over 65 years old are at 6.1 times greater risk
for pneumonia infection and over 10 times more likely to be hospitalized with pneumococcal pneumonia versus healthy adults.
About Blue Water Vaccines
Blue Water Vaccines Inc. is a biopharmaceutical company focused on
developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds
the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center, and St. Jude
Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition
to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children's
to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water
Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious
middle ear infections, known as Acute Otitis Media (AOM), in children. For more information, visit www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within
the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking
words such as "anticipate," "believe," "forecast," "estimate," "expect," and
"intend," among others. These forward-looking statements are based on BWV's current expectations and actual results
could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to, risks related to the development of BWV's vaccine candidates;
the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global
COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited
research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development,
there are significant risks in the development, regulatory approval and commercialization of new products. BWV does not undertake an obligation
to update or revise any forward-looking statement. Investors should read the risk factors set forth in BWV's Annual Report on Form
10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (the "SEC") on March 31,
2022, Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on August 15, 2022 and periodic reports filed
with the SEC on or after the date thereof. All of BWV's forward-looking statements are expressly qualified by all such risk factors
and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Media Contact Information:
Blue Water Media Relations
Telephone: (646) 942-5591
Investor Contact Information:
Blue Water Investor Relations